The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling
暂无分享,去创建一个
[1] E. Gluckman,et al. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft‐ and transplantation‐related factors , 2009, British journal of haematology.
[2] J. Armitage,et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Anna K. Marciniak-Czochra,et al. Characterization of stem cells using mathematical models of multistage cell lineages , 2011, Math. Comput. Model..
[4] R. Storb,et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.
[5] L. Schwartzberg,et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.
[6] A. Zander,et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment‐related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T‐cell depletion with anti‐thymocyte globulin , 2001, British journal of haematology.
[7] Willi Jäger,et al. Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. , 2009, Stem cells and development.
[8] L. Gil,et al. Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia. , 2009, Transplantation proceedings.
[9] H. Broxmeyer,et al. New approaches for improving engraftment after cord blood transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] P. Chevallier,et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: a comparison with matched unrelated donors as stem cell source , 2010, Bone Marrow Transplantation.
[11] D R Sutherland,et al. Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+CD90- hematopoietic progenitors. , 2001, Blood.
[12] H. Tanke,et al. Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation. , 2003, Blood.
[13] L. To,et al. CELL-DOSE EFFECT IN CIRCULATING STEM-CELL AUTOGRAFTING , 1986, The Lancet.
[14] J. Herman,et al. Association between antibodies reactive with neutrophils, rate of neutrophil engraftment, and incidence of post-engraftment neutropenia following BMT. , 1996, Bone marrow transplantation.
[15] M. Pasquini,et al. EFFECTS OF SPLEEN STATUS ON EARLY OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION , 2012, Bone Marrow Transplantation.
[16] D. Klatzmann,et al. Delayed recovery after autologous peripheral hematopoietic cell transplantation: potential effect of a high number of total nucleated cells in the graft , 2010, Transfusion.
[17] N. Schmitz,et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation , 1998, Bone Marrow Transplantation.
[18] K. Kawa,et al. Allogeneic hematopoietic transplantation of CD34+ selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood , 2000, Bone Marrow Transplantation.
[19] M. Voss,et al. Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation , 2012, Bone Marrow Transplantation.
[20] L. To,et al. How I treat patients who mobilize hematopoietic stem cells poorly. , 2011, Blood.
[21] D. Lu,et al. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients , 2013, Transplant infectious disease : an official journal of the Transplantation Society.
[22] S. Chevret,et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. , 2004, Experimental hematology.
[23] R. Powles,et al. Delayed engraftment associated with splenomegaly in patients undergoing bone marrow transplantation for chronic myeloid leukaemia. , 1990, Bone marrow transplantation.
[24] Michael C Mackey,et al. G-CSF treatment of canine cyclical neutropenia: a comprehensive mathematical model. , 2007, Experimental hematology.
[25] Yu-Hong Chen,et al. Long‐term follow‐up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia , 2013, Cancer.
[26] K. Ballen,et al. Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. , 2012, Blood.
[27] C. Salgado,et al. Challenges and advances in infection control of hematopoietic stem cell transplant recipients. , 2011, Infectious Diseases - Drug Targets.
[28] Michael C Mackey,et al. Dynamic hematological disease: a review , 2009, Journal of mathematical biology.
[29] R. Nuscher,et al. Bone marrow transplantation. , 1977, The American journal of nursing.
[30] K. Ballen,et al. Umbilical Cord Blood Transplantation , 2015, Journal of intensive care medicine.
[31] F. Aranha,et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies , 1998, Bone Marrow Transplantation.
[32] M. Martelli,et al. The haploidentical option for high-risk haematological malignancies. , 2008, Blood cells, molecules & diseases.
[33] C. Brunstein,et al. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival , 2011, Bone Marrow Transplantation.
[34] Y. Kanda,et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. , 2009, Blood.
[35] J. Adamson,et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.
[36] B. Lord. Myeloid cell kinetics in response to haemopoietic growth factors. , 1992, Bailliere's clinical haematology.
[37] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[38] Matt Post,et al. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single‐center study of 166 transplanted patients , 2007, Transplant infectious disease : an official journal of the Transplantation Society.
[39] E. Shpall,et al. Infections in 100 Cord Blood Transplantations: Spectrum of Early and Late Posttransplant Infections in Adult and Pediatric Patients 1996-2005 , 2007, Medicine.
[40] N. Mahmud,et al. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation , 2006, Bone Marrow Transplantation.
[41] L. Rybicki,et al. Apheresis days required for harvesting CD34+ cells predicts hematopoietic recovery and survival following autologous transplantation , 2011, Bone Marrow Transplantation.
[42] H. Deeg,et al. Who is fit for allogeneic transplantation? , 2010, Blood.
[43] J. Gribben,et al. Early neutrophil engraftment following autologous BMT provides a functional predictor of long‐term hematopoietic reconstitution , 2003, Transfusion.
[44] Stefan Fruehauf,et al. Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2007, European journal of haematology.
[45] M. Scholz,et al. Modelling Human Granulopoiesis under Poly-chemotherapy with G-CSF Support , 2005, Journal of mathematical biology.
[46] P. Cony-Makhoul,et al. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience , 1998, Bone Marrow Transplantation.
[47] N. Puig,et al. Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation , 2007, Leukemia & lymphoma.
[48] J. Ritz,et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. , 2011, Blood.
[49] R. Bannister. CHRONIC AUTONOMIC FAILURE WITH POSTURAL HYPOTENSION , 1979, The Lancet.
[50] J. Bodmer,et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. , 2004, Tissue antigens.
[51] Markus Scholz,et al. A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. , 2004, Blood.
[52] S. B. Mckenzie. Textbook of Hematology , 1988 .
[53] Michael C Mackey,et al. A mathematical model of hematopoiesis: II. Cyclical neutropenia. , 2005, Journal of theoretical biology.
[54] Ingo Roeder,et al. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. , 2002, Experimental hematology.
[55] Wolfgang Wagner,et al. Modeling of replicative senescence in hematopoietic development , 2009, Aging.